Microparticles for the delivery of DNA vaccines

Immunological Reviews

Volumn 199, Issue , 2004, Pages 191-200

  O'Hagan, Derek T ^a   Singh, Manmohan ^a   Ulmer, Jeffrey B ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; POLYGLACTIN;

ADSORPTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; BIOLOGY; CELL ENCAPSULATION; CELL INVASION; CELLULAR IMMUNITY; DNA TRANSFECTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; FACILITATION; GENE EXPRESSION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MICROENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS ATTENUATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; HUMANS; LACTIC ACID; MICE; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; VACCINATION; VACCINES, DNA;

EID: 2942601682     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00153.x     Document Type: Review

References (76)

1. Parker SE, et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999;10:741-758.
2. Parker SE, et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001;8:1011-1023.
3. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
4. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.
5. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, optimization Annu Rev Immunol 2000;18:927-974.
6. Wang R, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
7. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19:764-778.
8. Fu TM, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-371.
9. Ulmer J, Deck R, Dewitt C, Donnelly J, Liu M. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunol 1996;89:59-67.
10. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996;184:1555-1560.
11. Corr M, von Damm A, Lee DJ, Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 1999;163:4721-4727.
12. + T cells after gene gun immunization. J Exp Med 1998;188:1075-1082.
13. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997;159:11-14.
14. Sato Y, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
15. Klinman D, Yamshchikov G, Ishigatsubo Y. Contribution of CpG Motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635-3639.
16. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
17. Spies B, et al. Vaccination with plasmid DNA activates dendritic cells via toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003;171:5908-5912.
18. Dupuis M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000;165:2850-2858.
19. Widera G, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635-4640.
20. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999;6:508-514.
21. Timares L, Takashima A, Johnston SA. Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc Natl Acad Sci USA 1998;95:13147-13152.
22. Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997;61:125-132.
23. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-1968.
24. Kanke M, Sniecinski I, DeLuca PP. Interaction of microspheres with blood constituents. I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J Parenter Sci Technol 1983;37:210-217.
25. Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of 1-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 1988;22:837-858.
26. Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv Polym Sci 1990;94:107-141.
27. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999;11:753-761.
28. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly (D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002;19:1480-1487.
29. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 2002;60:480-486.
30. O'Hagan DT. Intestinal translocation of particulates - implications for drug and antigen delivery. Adv Drug Deliv Rev 1990;5:265-285.
31. O'Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 1996;189:477-482.
32. Jepson MA, Simmons NL, O'Hagan DT, Hirst BH. Comparison of poly (DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target 1993;1:245-249.
33. O'Hagan DT, Palin K, Davis SS, Artursson P, Sjoholm I. Microparticles as potentially orally active immunological adjuvants. Vaccine 1989;7:421-424.
34. O'Hagan DT, Palin KJ, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral wb=0.23w> immunization. Vaccine 1989;7:213-216.
35. Eldridge JH, Meulbroek JA, Staas JK, Tice TR, Gilley RM. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989;251:191-202.
36. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O'Hagan DT. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 1992;76:164-168.
37. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990;11:205-214.
38. O'Hagan D. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998;34:305-320.
39. Jones DH, McBride BW, Thornton C, O'Hagan DT, Robinson A, Farrar GH. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect Immun 1996;64:489-494.
40. Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH. Poly(DL-lactide-co- glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997;15:814-817.
41. Chen SC, et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998;72:5757-5761.
42. Kaneko H, et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000;267:8-16.
43. Mathiowitz E, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997;386:410-414.
44. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy [see comments]. Nat Med 1999;5:387-391.
45. O'Hagan D, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003;2:269-283.
46. Singh M, Vajdy M, Gardner J, Briones M, O'Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 2002;20:594-602.
47. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991;59:2978-2986.
48. O'Hagan DT, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991;73: 239-242.
49. O'Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine 1991;9:768-771.
50. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993;11:965-969.
51. O'Hagan DT, et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 2000;18:1793-1801.
52. O'Hagan DT, Singh M, Gupta RK. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 1998;32:225-246.
53. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 2000;67:347-356.
54. Otten GR, et al. Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J Virol 2003;77:6087-6092.
55. Singh M, et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 2004;93:273-282.
56. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994;81:661-667.
57. + Th1 cells. Vaccine 1995;13:1741-1749.
58. Nixon DF, et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996;14:1523-1530.
59. Seder RA, Gurunathan S. DNA vaccines - designer vaccines for the 21st century. N Engl J Med 1999;341:277-278.
60. Calarota S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320-1325.
61. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
62. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-609.
63. Amara RR, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
64. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 1998;4:365-368.
65. Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. J Control Release 1999;61:361-374.
66. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA. preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 1999;88:126-130.
67. Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J Control Release 2000;66:229-241.
68. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000;97:811-816.
69. O'Hagan D, et al. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J Virol 2001;75:9037-9043.
70. Briones M, et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res 2001;18:709-711.
71. Denis-Mize KS, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000;7:2105-2112.
72. Ott G, et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Control Release 2002;79:1-5.
73. Singh M, Ugozzoli M, Briones M, Kazzaz J, Soenawan E, O'Hagan D. The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm Res 2003;20:244-248.
74. Denis-Mize K, et al. Mechanisms of increased immunogenicity for DNA-based vaccines absorbed onto cationic microparticles. Cell Immunol 2003;225:12-20.
75. Klencke B, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8:1028-1037.
76. Sheets EE, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16, E7 plasmid DNA. Am J Obstet Gynecol 2003;188:916-926.